Observation: Brief Research Report

Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015

Background: Over the past 2 decades, prescription opioid sales and overdose deaths have quadrupled (1). Risk for unintentional overdose is increased when longer-acting opioids and higher dosages are prescribed (2, 3). Older patients are particularly vulnerable to opioid-related complications and injury (4). Addressing these risks, the 2016 opioid prescribing guidelines from the Centers for Disease Control and Prevention (2) suggest a trial of nonopioid therapies before opioid initiation, use of opioids only when expected benefits outweigh risks, reassessment of risks and benefits when prescribing dosages greater than 50 morphine milligram equivalents (MME) per day, and prescribing no more than 90 MME/d.

Restricting formulary coverage for prescription drugs is 1 strategy to decrease opioid prescribing. A private insurer showed that implementing prior authorization, quantity limits, and provider–patient agreements was associated with a 15% decrease in opioid prescribing (5). The extent to which opioids are covered and/or restricted among formularies serving Medicare beneficiaries is unknown.

Objective: To characterize the extent to which utilization management strategies have been used to restrict access to prescription opioids among Medicare Part D formularies over the past decade.

Methods and Findings: We used the Centers for Medicare & Medicaid Services prescription drug plan formulary files to compare coverage in 2006, 2011, and 2015 for all available doses of commonly used short- and long-acting opioid medications except for methadone, which was excluded. These files include data on all Medicare Advantage and standalone Part D plan formularies that have submitted complete and accurate information to the Centers for Medicare & Medicaid Services. Although lack of formulary coverage may not be intended to restrict opioid prescribing, it creates a financial barrier to prescription opioid access.

We determined the median proportion of drug–dosage combinations that formularies did not cover; covered but did not restrict; and restricted through prior authorization, step therapy, or quantity limits. We also calculated whether prescribed dosages were limited to less than 50 MME/d or 50 to 90 MME/d or whether those greater than 90 MME/d were permitted. We graphed results for hydrocodone–acetaminophen, a commonly prescribed short-acting opioid frequently implicated in overdose-related deaths, to show our findings at the individual drug level.

Data were available for 324, 244, and 389 formularies in 2006, 2011, and 2015, respectively. In 2006 and 2011, more than two thirds of drug–dosage combinations had no opioid prescribing restrictions; in 2015, approximately one third had no restrictions (Table). Few formularies required step therapy, but requirements for prior authorization increased over time (from a median of 0% in 2006 and 2011 to 4.4% in 2015). The median proportion of drug–dosage combinations with quantity limits increased from 8.9% in 2006 to 22.2% in 2011 and 71.1% in 2015. Dose restrictions to less than 50 MME/d increased from a median of 2.2% of drug–dose combinations in 2006 to 4.4% in 2011 and 13.3% in 2015.

Formularies increased coverage for hydrocodone–acetaminophen at all dosages between 2006 and 2015 (Figure). Although no formularies required prior authorization or step therapy for this drug, the daily dosage was increasingly restricted for the 5 mg/325 mg and 7.5 mg/325 mg formulations, with a greater proportion limiting prescriptions to less than 90 MME/d between 2006 and 2015. Restrictions on MME per day for the 10 mg/325 mg formulation increased slightly from 2011 to 2015, with approximately 80% permitting prescribing greater than 90 MME/d in 2015.

Discussion: Medicare Part D formularies increasingly used quantity limits and, to a lesser extent, prior authorization to restrict daily allowable prescribed dosing of prescription opioids between 2006 and 2015. Despite increased formulary restrictiveness, unrestricted coverage persisted for many opioids, especially at high doses, including for drugs commonly associated with overdose. Although the overall number of formularies with available data varied across years, changes in how many formularies provided information are unlikely to have affected this general trend.

As shown by formulary coverage of hydrocodone–acetaminophen, formularies tended to be less restrictive at higher doses, largely because they maintained identical quantity limits regardless of dose. This factor allowed for higher prescribed MME per day. Given that higher doses are associated with higher overdose rates (3), limiting prescribed MME per day or requiring prior authorization or step therapy for high-dose opioids may facilitate better adherence to Centers

<table>
<thead>
<tr>
<th>Formulary Coverage</th>
<th>2006 Formularies (n = 324)</th>
<th>2011 Formularies (n = 244)</th>
<th>2015 Formularies (n = 389)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No coverage</td>
<td>20 (13.3–35.6)</td>
<td>15.6 (4.4–24.4)</td>
<td>17.8 (11.1–33.3)</td>
</tr>
<tr>
<td>Coverage with no restrictions</td>
<td>66.7 (51.1–80.0)</td>
<td>66.7 (53.5–77.8)</td>
<td>33.3 (28.9–44.4)</td>
</tr>
<tr>
<td>Requires prior authorization</td>
<td>0 (0–4.4)</td>
<td>0 (0–8.9)</td>
<td>4.4 (0–11.1)</td>
</tr>
<tr>
<td>Requires step therapy</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
</tr>
<tr>
<td>Imposes any quantity limit</td>
<td>8.9 (0–26.9)</td>
<td>22.2 (8.9–40.6)</td>
<td>71.1 (60.0–84.4)</td>
</tr>
<tr>
<td>Imposes a specific quantity limit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50 MME/d</td>
<td>2.2 (0–6.7)</td>
<td>4.4 (2.2–6.7)</td>
<td>13.3 (8.9–17.8)</td>
</tr>
<tr>
<td>50–90 MME/d</td>
<td>2.2 (0–8.9)</td>
<td>6.7 (4.4–13.3)</td>
<td>24.4 (20.0–33.3)</td>
</tr>
<tr>
<td>&gt;90 MME/d</td>
<td>4.4 (0–13.3)</td>
<td>11.1 (2.2–24.4)</td>
<td>31.1 (26.7–37.8)</td>
</tr>
</tbody>
</table>

MME = morphine milligram equivalents.

* Values are percentages, and values in parentheses are interquartile ranges.
for Disease Control and Prevention prescribing recommendations. Because formulary coverage directly affects prescribing, our study suggests that formularies present an underutilized opportunity to restrict opioid prescribing.

Elizabeth A. Samuels, MD, MPH
Yale University, Yale New Haven Hospital, and Veterans Affairs Connecticut Healthcare System
New Haven, Connecticut

Joseph S. Ross, MD, MHS
Yale University and Yale New Haven Hospital
New Haven, Connecticut

Sanket S. Dhruva, MD, MHS
Yale University and Veterans Affairs Connecticut Healthcare System
New Haven, Connecticut

Disclaimer: The authors assume full responsibility for the accuracy and completeness of the ideas presented, which do not represent the views of the U.S. Department of Veterans Affairs or any other supporting intuitions.

Financial Support: This project was not supported by any external grants or funds. Dr. Samuels is supported by the National Clinician Scholars Program. Dr. Dhruva is supported by the Robert Wood Johnson Foundation Clinical Scholars Program. Drs. Samuels and Dhruva are supported by the U.S. Department of Veterans Affairs.

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-1823.

Reproducible Research Statement: Study protocol and statistical code: Available from Dr. Samuels (e-mail, elizabeth.samuels@yale.edu). Data set: Available for purchase from the Centers for Medicare & Medicaid Services (www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/NonIdentifiableDataFiles/PrescriptionDrugPlanFormularyPharmacyNetworkandPricingInformationFiles.html).

This article was published at Annals.org on 10 October 2017.
doi:10.7326/M17-1823

References